Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 32Radiotherapy 11Bevacizumab 10Surgical Procedures, Operative 7IL13-PE38 7TIC10 compound 6Lomustine 6Carboplatin 6Radiation 5Chlorotoxin 5vorasidenib 4trametinib 4dabrafenib 4Valacyclovir 4OKN 007 4Flucytosine 4Dianhydrogalactitol 4Cyclophosphamide 4vocimagene amiretrorepvec 3abemaciclib 3Paclitaxel 3Nivolumab 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3CLR1404 3trans-sodium crocetinate 2pembrolizumab 2olutasidenib 2marizomib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioma × dinutuximab × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡